CLINICAL TRIALS PROFILE FOR HUMAN RABIES VIRUS IMMUNE GLOBULIN
✉ Email this page to a colleague
All Clinical Trials for human rabies virus immune globulin
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02040090 ↗ | Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects | Completed | Kamada, Ltd. | Phase 2/Phase 3 | 2013-04-01 | The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine. |
NCT02564471 ↗ | Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. | Completed | Kansas State University | Phase 4 | 2016-11-11 | This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen. |
NCT02564471 ↗ | Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. | Completed | Walter Reed Army Institute of Research (WRAIR) | Phase 4 | 2016-11-11 | This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen. |
NCT02564471 ↗ | Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. | Completed | State University of New York - Upstate Medical University | Phase 4 | 2016-11-11 | This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for human rabies virus immune globulin
Condition Name
Clinical Trial Locations for human rabies virus immune globulin
Trials by Country
Clinical Trial Progress for human rabies virus immune globulin
Clinical Trial Phase
Clinical Trial Sponsors for human rabies virus immune globulin
Sponsor Name